Jagsonpal Pharmaceuticals Limited — Investor Meet, 13-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharmaceuticals has announced a board meeting to consider the financial results for the quarter and half-year.

Q4FY25 revenue rose 34.7% to ₹58.6 Cr, EBITDA nearly doubled to ₹9.7 Cr with margin up 530 bps at 15.6%, and PAT increased 88.5% to ₹6.6 Cr (11.2% margin). FY25 revenue grew 28.8% to ₹268.7 Cr, EBITDA jumped 59% to ₹57.9 Cr (21.5% margin), and PAT more than doubled to ₹55.4 Cr (20.6% margin). Cash balance was ₹145 Cr.

Management highlighted a focus on niche products and acquisitions, with inorganic growth contributing ~20% and organic growth improving. Working capital efficiency improved sharply, while field force productivity targets a 50% increase in 3–4 years. The company pursues an asset-light model, targeting 15%+ revenue growth and margin expansion of 100–150 bps annually. Strategic emphasis remains on margin expansion, disciplined acquisitions, and sustainable growth.